GBLX

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Retrieved on: 
Thursday, December 22, 2022
MEM, OTCQB, Bi-specific T-cell engager, Research, COVID-19, Biomarker, Virus, USD, CAR, CRS, Patient, Michigan State University, Degenerative disease, Syndrome, Innovation, Cytokine, Cannabinoid, Therapy, Cytokine release syndrome, Immune system, GBLX, Bispecific monoclonal antibody, Vaccine, Pharmaceutical industry

Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.

Key Points: 
  • Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.
  • "Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation.
  • Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here .
  • A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers.

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

Retrieved on: 
Monday, December 12, 2022
Good manufacturing practice, Michigan State University, Lighthouse, Parkinson's disease, Depression, Clinical trial, Research, Nature, Security (finance), Chronic pain, National Research Council, National Research Council Canada, Hospital, GBLX, Cytokine release syndrome, NRC, University, OTCQB, Kava, Scale, Attention, Patient, Anxiety, GBS, Pharmaceutical industry

LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic.

Key Points: 
  • LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic.
  • Approximately 300 million people in the world suffer from anxiety and depression, while effective clinical treatments are still limited globally.
  • Gb Sciences has leveraged its AI-enabled drug discovery technology to develop kava plant-inspired treatments for anxiety and depression that are designed to enhance mood but are non-psychedelic.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada.

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

Retrieved on: 
Tuesday, November 1, 2022
Olive, Security (finance), THC, Depression, Nature, National Research Council, Food and Chemical Toxicology, Cannabinol, Assay, Inflammation, U.S. Securities and Exchange Commission, GBLX, CBC, Chaminade University of Honolulu, CBDV, Good manufacturing practice, Biomarker, Clinical trial, GLOBE, Parkinson's disease, Hospital, COVID-19, Immune system, Michigan State University, CBN, Cannabinoid, Terpene, Anxiety, University, Cannabidiol, Company, CBG, Prevalence, Cytokine release syndrome, Contract, Sativum, OTCQB, Chronic pain, Nonsteroidal anti-inflammatory drug, Pharmaceutical industry, CBD, Cannabis

Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.

Key Points: 
  • Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.
  • Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies.
  • Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada.

TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

Retrieved on: 
Thursday, October 27, 2022
Contract, Michigan State University, Drug discovery, Clinical trial, Good manufacturing practice, Depression, Chronic pain, Hospital, Cytokine release syndrome, Machine learning, Anxiety, University, Database, IDC, Patient, Industry, GLOBE, Use, Parkinson's disease, National Research Council, Time, GBLX, Plant, Pharmaceutical industry

LAS VEGAS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC) , a leading plant-inspired, biopharmaceutical research and drug development company,is demonstrating their AI-enabled drug discovery engines' ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California.

Key Points: 
  • LAS VEGAS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC) , a leading plant-inspired, biopharmaceutical research and drug development company,is demonstrating their AI-enabled drug discovery engines' ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California.
  • In her session entitled "The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals," Dr. Small-Howard will introduce PhAROS, Gb Sciences' proprietary AI-enabled drug discovery platform.
  • "Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools.
  • Our AI-enabled drug discovery platform also reduces the time and money needed to get results," said Dr. Andrea Small-Howard.

Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Time, Michigan State University, GBLX, NRC, Cytokine release syndrome, Hospital, Depression, Parkinson's disease, Kava, Security (finance), GBS, Good manufacturing practice, Company, Drug discovery, National Research Council, Nature, Research, University, Liver, GLOBE, Clinical trial, Anxiety, Chronic pain, Contract, Fine chemical, Pharmaceutical industry, Piper

GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study.

Key Points: 
  • GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study.
  • "We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations.
  • Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC).

TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Retrieved on: 
Thursday, October 13, 2022
Adoption, Canna, U.S. Securities and Exchange Commission, Maxima and minima, Michigan State University, Therapy, ODT, GBLX, Conference, Almanac, Smoking, Area studies, Quality control, Cytokine release syndrome, Hospital, Parkinson's disease, Depression, Security (finance), Inflammation, Herbal cigarette, Good manufacturing practice, Company, OTCQB, OTF, Nature, National Research Council Canada, Safety, University, GLOBE, Clinical trial, Anxiety, Chronic pain, Contract, MEM, Pharmaceutical industry, Pharma

Dr. Small-Howard explains Gb Sciences' novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled "Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models."

Key Points: 
  • Dr. Small-Howard explains Gb Sciences' novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled "Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models."
  • Minimal essential mixtures (MEM) is a term Gb Sciences has coined from their proprietary research after deeming that a simplified mixture represented a happy medium between whole plant medicines and single ingredient drugs.
  • Minimum Essential Mixtures are designed to retain increased therapeutic effectiveness from molecular synergies within the original plant extracts, but with the manufacturing efficiencies, quality assurances, and regulatory advantages of single ingredient drugs.
  • The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices.

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

Retrieved on: 
Monday, October 10, 2022
Chaminade University of Honolulu, U.S. Securities and Exchange Commission, Michigan State University, Disease, Therapy, GBLX, PD, NRC, Tablet, IND, Cannabinoid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Zebrafish, University of Lethbridge, Cytokine release syndrome, Parkinson's disease, Depression, Research, Hospital, Security (finance), Drug discovery, University, Food, Good manufacturing practice, Company, Contract, National Research Council, Nature, GLOBE, Frontiers Media, Clinical trial, Anxiety, Chronic pain, MEM, Toxicology, Pharmaceutical industry, Pharmacology, Parkinsonism

(OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company,has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD).

Key Points: 
  • (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company,has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD).
  • Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences.
  • "This study allows us to continueaddressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
  • Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial.

TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

Retrieved on: 
Tuesday, September 6, 2022
Chronic pain, Security (finance), COVID-19, University, Good manufacturing practice, Plant, Contract, National Research Council Canada, Anxiety, Hospital, U.S. Securities and Exchange Commission, Tablet, Depression, Michigan State University, GLOBE, Cytokine release syndrome, GBLX, Company, Pharma, Parkinson's disease, Drug discovery, Clinical trial, Drug development, OTCQB, Nature, Pharmaceutical industry

LAS VEGAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company,describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma's Almanac today at https://www.pharmasalmanac.com/articles/unlocking-the-therapeutic-potent... .

Key Points: 
  • LAS VEGAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company,describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma's Almanac today at https://www.pharmasalmanac.com/articles/unlocking-the-therapeutic-potent... .
  • The full article entitled " Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures " also provides some context for their recent drug development successes by discussing Gb Sciences' evolution from a cannabis company to a plant-inspired biopharmaceutical company and what makes their drug development approach truly unique.
  • In its drug development pipeline, Gb Sciences has five preclinical phase product development programs.
  • Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations.

TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit

Retrieved on: 
Monday, May 23, 2022
1836 U.S. Patent Office fire, Contract, University, Company, Harvard University, U.S. Securities and Exchange Commission, GBLX, Neurodegeneration, US FDA, Patient, National Research Council Canada, US, Nature, Clinical trial, COVID-19, Good manufacturing practice, 2004 Democratic National Convention keynote address, Depression, Investigational New Drug, Neuron, Cytokine release syndrome, Human, Anxiety, Hospital, Chronic pain, Keynote, Ageing, University of Lethbridge, Therapy, Michigan State University, OTCQB, National Research Council, Security (finance), GLOBE, Pharmaceutical industry, Neurology, Parkinson's disease

LAS VEGAS, May 23, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX) , presents a Keynote Address today at this year's NeuroForum Summit on the theme of "Emerging Perspectives in Neurology and Brain Research".

Key Points: 
  • LAS VEGAS, May 23, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX) , presents a Keynote Address today at this year's NeuroForum Summit on the theme of "Emerging Perspectives in Neurology and Brain Research".
  • "A multi-factorial disorder like Parkinson's disease may require a multicomponent drug like ours to successfully manage the symptoms," said Dr. Small Howard.
  • In 2020, the combined direct and indirect costs associated with Parkinson's disease in the United States were estimated at approximately $52 billion.
  • Although the precise causes of Parkinson's disease are unknown, several variables , such as aging, genetic predisposition, and environmental factors or exposure contribute to the disease's progression.

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

Retrieved on: 
Thursday, May 12, 2022
Inflammation, Contract, University, Company, Plant, Parkinson's disease, Research, Degenerative disease, U.S. Securities and Exchange Commission, GBLX, Drug discovery, National Research Council Canada, Metabolic syndrome, Nature, ALCOR, Clinical trial, COVID-19, Good manufacturing practice, Depression, Cytokine release syndrome, Anxiety, Hospital, Safety, Chronic pain, Drug development, Machine learning, Security (finance), Michigan State University, Growth, OTCQB, Lists of diseases, GLOBE, Pharmaceutical industry

"Demonstrating the capabilities of our novel drug discovery platform at ALCOR's 2nd Drug Discovery Platform Summit provides us with an opportunity to engage with scientists, researchers, and decision-makers representing over 120 companies from all over the world," says Dr. Small-Howard.

Key Points: 
  • "Demonstrating the capabilities of our novel drug discovery platform at ALCOR's 2nd Drug Discovery Platform Summit provides us with an opportunity to engage with scientists, researchers, and decision-makers representing over 120 companies from all over the world," says Dr. Small-Howard.
  • Gb Sciences' proprietary minimum essential mixtures are designed to retain the efficacy of whole plant therapies while maintaining the manufacturing and quality control advantages of single-ingredient pharmaceutical products.
  • As Gb Sciences' drug development pipeline advances these drug candidates into human clinical trials, the value of the PhAROS drug discovery platform increases, thus, becoming an important asset for the future growth of the company.
  • In its drug development pipeline, Gb Sciences has five preclinical phase product development programs.